anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Prior research has demonstrated an association between sodium-glucose cotransporter 2 (SGLT2) inhibitor and a reduced incidence of atrial fibrillation (AF). Given the established link between mitochondrial dysfunction and AF, this study aimed to explore the impact of SGLT2 inhibitors on AF burden and plausible antiarrhythmic mechanisms in patients with cardiovascular implantable electronic devices (CIEDs). Patients with atrial high-rate episodes (AHREs) detected by CIEDs were randomized to receive either 10 mg of dapagliflozin or a placebo for 3 months. AF burdens were quantified via CIEDs interrogations as AHREs duration, percentage, and number of episodes at baseline and after 3 months of treatment. Mitochondrial parameters, cellular oxidative stress, and norepinephrine levels were measured in peripheral blood mononuclear cells (PBMCs). A total of 54 patients with CIEDs were enrolled in the study. Among them, 36 patients (66.7%) had a history of clinical AF, and 9 patients (16.7%) had diabetes mellitus. After 3 months of the assigned treatment, the median longest AHRE duration decreased similarly in both the dapagliflozin and placebo groups (-77.0 vs. -162.0 min, p = 0.442). Clinical AF, as opposed to subclinical AF, was independently linked to decreased basal respiration and adenosine triphosphate (ATP) production. Although the changes in AHREs burden over the 3 months did not significantly differ between the dapagliflozin and placebo groups, dapagliflozin significantly decreased the number of AHREs per month by 2.2 episodes among patients with clinical AF, whereas the placebo group experienced an increase of 0.6 episodes (p = 0.048). Additionally, dapagliflozin significantly reduced cellular oxidative stress (from 26840 to 18164 arbitrary units, p = 0.049) and improved mitochondrial spare respiratory capacity (SRC) percentage (from 166 to 202%, p = 0.016) in patients with clinical AF. Dapagliflozin did not significantly reduce the longest AHRE duration in patients with CIED. However, in the subgroup of patients with clinical AF, dapagliflozin reduced the number of AHREs potentially via reduction of cellular oxidative stress and enhancement of mitochondrial function.The study protocol was registered at the Thai Clinical Trials Registry (TCTR identification number TCTR20210315003) on March 15, 2021.
PURPOSE:To obtain a thyroid function improver for preventing and improving functional disorder of thyroid tissue and symptoms and sequela caused by the disorder, comprising a benzothienopyridine as an active ingredient. CONSTITUTION:The thyroid function improver comprises a compound of formula I of formula II (R1 is alkoxy, amino, hydrazino or N-containing heterocyclic group; R2 and R3 are halogen, alkyl, aryl, alkenyl, acyl, etc.; m and n are 0-4; etc.) such as benzo[b]thieno[2, 3-c]pyridine-3-carboxylic acid methyl ester as an active ingredient. In the case of pharmaceutical manufacturing of the compound into capsule, tablet, granule or powder form, 1-80wt.% of the compound is contained, in the case of to injection, 0.01-20wt.% of the compound is contained and in the case of into syrup and suspension is 0.01-20wt.% of the compound is contained. The improver is effective against thyroidism, Basedow's disease, Plummer's disease, cretin disease, insanity and intelectural disturbance caused by hypothyroidism, Paget's disease, osteoporosis, etc.
After sterilization, disposable sterilized needles (0.25 × 40 mm, Taichi disposable acupuncture needles, Suzhou Shenlong Medical Apparatus Company, Suzhou, China) are inserted by the Registered Chinese Medicine Practitioner (RCMP) into the acupoints of Shenting (GV24), left Benshen (GB13), right Benshen (GB13), Baihui (GV20), and Sishencong (EX-HN 1). Acupoints are then stimulated by the Huatuo SDZ-II electroacupuncture device.
Participants received 4 doses of GRF6021, 250 milliliters (mL), intravenous (IV) infusion. The first dose was administered on day before surgery, the next two doses on the day of surgery i.e., within 4 hours before start of surgery (first incision), and then upon arrival in the postoperative care unit (within 5 hours after the first incision) and the last dose was administered on the day after the surgery.
Bexarotene selectively binds and activates retinoid X receptor subtypes (RXRα, RXRß, RXRγ). RXRs can form heterodimers with various receptor partners such as retinoic acid receptors (RARs), vitamin D receptor, thyroid receptor, and peroxisome proliferator activator receptors (PPARs). Once activated, these receptors function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of some tumor cell lines of hematopoietic and squamous cell origin. It also induces tumor regression in vivo in some animal models. The exact mechanism of action of bexarotene in the treatment of cutaneous T-cell lymphoma (CTCL) is unknown.
Pulmonary fibrosis is a severe and progressive lung disease characterized by lung tissue scarring. Transforming growth factor beta 1 (TGFβ1) is crucial in causing pulmonary fibrosis by promoting the activation of fibroblasts and their differentiation into myofibroblasts, which are responsible for excessive extracellular matrix deposition. This study aimed to identify genes activated by TGFβ1 that promote fibrosis and to understand the regulatory pathway controlling myofibroblast. Endothelin-1 (ET-1) was identified as the top-ranking gene in the fibrosis-related gene set using quantitative PCR array analysis. TGFβ1 upregulated EGR1 expression through the ERK1/2 and JNK1/2 MAPK pathways. EGR1 and p-SMAD2 proteins interacted with the ET-1 gene promoter region to regulate TGFβ1-induced ET-1 expression in IMR-90 pulmonary fibroblasts. Mice lacking the Egr1 gene showed reduced ET-1 levels in a model of pulmonary fibrosis induced by intratracheal administration of bleomycin. These findings suggest that targeting EGR1 is a promising approach for treating pulmonary fibrosis, especially idiopathic pulmonary fibrosis, by affecting ET-1 expression and profibrotic reactions.
OBJECTIVE: To assess cardiac troponin I and creatine kinase-myocardial band levels, electrocardiogram changes and major adverse cardiac events after treatment with nicorandil before primary percutaneous coronary intervention.
METHODS: The comparative, analytical study was conducted from October to November 2022 at the Pharmacology Department of Army Medical College, National University of Medical Sciences, Rawalpindi, Pakistan, in collaboration with the Rawalpindi Institute of Cardiology, Rawalpindi. The sample comprised ST-elevated myocardial infarction patients of either gender aged at least 30 years with an ejection fraction of at least 35% undergoing primary percutaneous coronary intervention. Participants were selected based on the above-mentioned inclusion and informed consent was taken before their enrolment in this research study. The sample was randomised into control group A receiving conventional acute coronary syndrome treatment, and intervention group B receiving nicorandil in addition to the conventional treatment. Cardiac troponin I and creatine kinase-myocardial band levels, electrocardiogram changes, and major adverse cardiac events noted and compared. Data was analysed using SPSS 26.
RESULTS: Of the 140 patients, 70(50%) were in each of the 2 groups. In group B, 60(85.7%) patients achieved a completely settled ST segment on electrocardiogram compared to 25(35.7%) in group A (p=0.001). There was a significant inter-group difference with respect to cardiac troponin I value 6 hours after percutaneous coronary intervention and major adverse cardiac events (p<0.05), but creatine kinase-myocardial band level was no significantly different between the groups (p=0.761).
CONCLUSION: Prophylactic use of nicorandil in ST-elevated myocardial infarction patients decreased the incidence of reperfusion injury.
African Americans account for half of all Americans currently living with AIDS, and men account for two-thirds of all African Americans with HIV. AAMSMW are at particular risk for contracting and transmitting HIV, and represent a priority population for developing effective interventions. Studies of AAMSMW conducted in multiple HIV-epicenters in the United States have reported high rates of unprotected intercourse with male and female partners, concurrent partnerships, and frequent substance use before sex, accompanied by non-disclosure and secrecy regarding sexual risk behaviors. These behavioral dynamics are likely to fuel transmission of HIV and other STDs in diverse sexual networks and communities. Despite the urgent need for effective prevention approaches for AAMSMW, to our knowledge no evidence-based HIV interventions have been developed and tested for this population.

We propose to test a behavioral prevention intervention, the BP, to reduce HIV-related sexual risk behavior among AAMSMW. The intervention was designed through four years of formative research with AAMSMW consisting of: (1) qualitative in-depth interviews, focus groups and field ethnography; (2) protocol and measure development; (3) pilot testing and evaluation; and (4) further refinement following process and preliminary outcome data. The BP counseling process was formulated on principles of the Information-Motivation-Behavior (IMB) theory of HIV prevention, and is characterized by an individual-level counseling process that is specifically tailored to recognize the social and cultural contexts that inform sexual behavior for AAMSMW. Delivered in a series of four sessions by trained African American male counselors, the BP focuses on reviewing HIV transmission routes for male and female partners, strengthening sexual communication skills with both male and female partners, and improving condom use skills and other safer sex negotiation strategies. Evidence thus far indicates that BP is an acceptable and feasible model for providing HIV prevention counseling to this population, and pilot outcome data show promising indications of behavior change. A team of trained BP staff have successfully utilized a multi-tiered outreach approach to identify AAMSMW, recruit eligible individuals, and engage and retain participants in a longitudinal evaluation design. A randomized controlled trial of BP is necessary to determine the efficacy of the intervention and can lead to improved public health efforts at reducing HIV risk behavior among AAMSMW and in the African American community more generally.
The young individuals in the intervention group will be informed about the study, including its purpose and methodology, and their consent will be obtained. Emotional Freedom Techniques (EFT) will be applied to groups of 20 individuals to improve sleep quality, and all scales will be administered beforehand. EFT will be applied twice, with a 15-day interval between sessions, and the same scale questionnaires will be administered again after the second EFT session. Subsequently, the analysis will be conducted.
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors, and the expression and function of an uncharacterized protein RNF214 in HCC are still unknown. Phase separation has recently been observed to participate in the progression of HCC. In this study, we investigated the expression, function, and phase separation of RNF214 in HCC. We found that RNF214 was highly expressed in HCC and associated with poor prognosis. RNF214 functioned as an oncogene to promote the proliferation, migration, and metastasis of HCC. Mechanically, RNF214 underwent phase separation, and the coiled-coil (CC) domain of RNF214 mediated its phase separation. Furthermore, the CC domain was necessary for the oncogenic function of RNF214 in HCC. Taken together, our data favored that phase separation of RNF214 promoted the progression of HCC. RNF214 may be a potential biomarker and therapeutic target for HCC.
A human antihuman IL-18 antibody originating in humans, which is an antibody against human IL-18, containing an H chain complementarity determining region comprising the following polypeptide (a) or (b) and an L chain complementarity determining region to human interleukin-18 comprising the following polypeptide (c) or (d). (a) A polypeptide consisting of an amino acid sequence represented by any of SEQ ID NOS:4 to 6. (b) A polypeptide which is a modification of the polypeptide (a) and serves as an H chain complementarity determining region. (c) A polypeptide consisting of an amino acid sequence represented by any of SEQ ID NOS:10 to 12. (d) A polypeptide which is a modification of the polypeptide (c) and serves as an L chain complementarity determining region. Thus, it becomes possible to provide a human antihuman IL-18 antibody and a method of using the same.
Coronavirus Disease 2019 (COVID-19) is the disease caused by a novel coronavirus SARS- CoV-2. In recovered COVID-19 patients, emerging global data have reported the presence of Long COVID, a condition where at least one symptom that cannot be explained by alternative diagnosis has been persistent for four or more weeks after the initial infection. We demonstrated previously that almost 80% of recovered COVID-19 patients in Hong Kong suffer from Long COVID for more than 6 months, affecting multiple body systems.

In a recent study, the five most common Long COVID symptoms were fatigue, memory problem, difficulty sleeping, anxiety and hair loss. Current treatment for Long COVID only involves symptomatic care, as the exact mechanisms underlying the pathogenesis are still largely unknown. One promising hypothesis is the involvement of the gut microbiota, a collection of the trillions of gut microorganisms that play important immunomodulatory roles against infections. Our recently published findings have shown that patients with Long COVID had a less diverse gut microbiota with significantly fewer health-associated commensal bacteria than those without Long COVID. Previous studies have also proved the association between the gut microbiota and insomnia, circadian disturbance and affective disorders. Thus, gut microbiota modulation could be a novel therapeutic strategy for these neuropsychiatric conditions.

Faecal microbiota transplantation (FMT), which is the infusion of faeces from healthy donors to the gut of affected subjects, has shown impressive therapeutic effects for various diseases. To date, no study has yet to assess the therapeutic effects of FMT in post-COVID-19 neuropsychiatric conditions. In this pilot open-label study, we aim to explore the efficacy of FMT in improving neuropsychiatric symptoms including but not limited to insomnia severity, sleep quality, anxiety and fatigue in recovered COVID-19 patients. FMT will be administrated via Oesophago-gastro-duodenoscopy (OGD) and Flexible Sigmoidoscopy (FS). Two arms will be recruited in a 1:1 ratio. The intervention group will receive FMT while the control group will not receive FMT. Both groups will have the same assessments. Subjects will receive FMT via OGD at week 0, week 2, week 4 and week 8, and via FS at week 0. Final follow-up will be scheduled at weeks 8 and 12 for clinical assessment. To assess the efficacy of FMT in improving neuropsychiatric symptoms, subjects will have to fill in study questionnaires at baseline, week 8 and week 12. Subjects will also be asked to fill in a sleep diary daily until week 12.
Midazolam at 0.1mg/kg BW, fentanyl at 1ug/kg BW, rocuronium bromide at 0.6mg/kg BW was given intravenously for induction intubation; After the intubation was completed, sufentanil at 0.1 μg/kg/h was administered for analgesia, and remazolam tosylate at an initial dose of 0.075 mg/kg/h was administered for sedation, and the dose of remazolam tosylate was adjusted according to the RASS score. The RASS score was assessed every 1 h and maintained at -2 to 0.
Nanoparticle-based vaccines, compositions, kits and methods are employed to efficiently deliver one or more antigens in vivo for immunization and antibody production (e.g., monoclonal antibodies), as well as to efficiently deliver peptides, proteins, siRNA, RNA or DNA to PAPC or MHC class II positive cells (e.g., tumor cells). For example, an antigen can be DNA that causes the expression of a gene of interest in a subject (e.g., a mammal) and induces a strong and specific immune response against the expressed protein. The antigen may also be an immunogenic peptide or polypeptide that is processed and presented. In one embodiment, the nanoparticle-based in vivo antigen delivery methods described herein comprise the injection of a vaccine consisting of DNA encoding at least one antigen, or at least one antigenic peptide or polypeptide, conjugated to a charged dendrimer (e.g., PADRE derived dendrimer), which is also conjugated to a T helper epitope (e.g., PADRE). Negatively charged plasmids naturally bind positively charged PADRE-dendrimers, whereas peptide or polypeptide antigens may be chemically linked to PADRE-dendrimers if they are not negatively charged. Alternatively, negatively charged dendrimers may be used. The compositions, kits, vaccines, and methods described herein have both prophylactic and therapeutic applications, i.e., can be used as a prophylactic to prevent the occurrence of a disease or disorder in a subject and to treat a subject suffering from or having a disease. The vaccines described herein can be used to generate an immune response against any infectious pathogen or cancer.
PURPOSE:To develop a dental ceramic material capable of high precision molding by mixing a specified amt. of Li compd. with calcium phosphate and melting the mixture under reduced pressure. CONSTITUTION:0.1-30pts.wt. Li compd. such as hydroxide, carbonate, chloride, nitrate, org. acid salt, of Li forming oxide during melting (basing on an amt. expressed in terms of Li2O) is added to 100pts.wt. calcium phosphate having 0.35- 1.7 atomic ration (Ca/P) in order to obtain a dental ceramic material capable of being shaped easily and optionally without lacking affinity to living body unlike conventional metal or plastics. Or, the material is prepd. by adding further a metal oxide as a coloring component for giving the material the same tone as the tooth of a living body. Obtd. material can be easily shaped to an optional shape by melting by heating under reduced pressure by such as lost-wax process.
A cognitive behavioral group prevention program An 8-session, cognitive behavioral group prevention program, featuring cultural appropriateness. One session per week, 3 hours for each session. The program contents include psychoeducation, cognitive skills training to identify and challenge maladaptive cognitions, and behavioral skills training. Each session contains mood check and homework. Participants' own examples are used in the group to demonstrate the CBT skills.
Random subsample of all 17-18-year-old individuals in Denmark, i.e. live births from year 2006 and 2007.
The Coping with Stress Program that consists of 8 sessions will be implemented to the experimental group. 8-10 adolescents will be included in this program. The session frequency will be one session per week. After the completion of 8 sessions, two 90-minute sessions will be carried out each month in the following two months.
PROBLEM TO BE SOLVED: To obtain a polyisoprenylated benzophenone derivative with no side effect, and useful for prophylactic of colon cancer. SOLUTION: This carcinogenesis prophylactic is obtained by including a polyisoprenylated benzophenone derivative (e.g. garcinol) The above-mentioned derivative is obtained, for example, by extraction from the fruits, peels or the like of Hypericaceae plant (e.g. Garcinia cambogia), using an organic solvent (e.g. ethanol) pref. at 1-100 times (weight ratio) the raw material, at >=0 deg.C for 1 min to 8 weeks. The content of the above-mentioned derivative in this prophylactic is desirable to be 0.00001-10 wt.%. The daily dose of the derivative is preferably 1-5,000 mg per adult. This prophylactic can be administered through any medication method of oral administration, external application and injection.
The kidney-brain axis is a bidirectional communication network connecting the kidneys and the brain, potentially affected by inflammation, uremic toxin, vascular injury, neuronal degeneration, and so on, leading to a range of diseases. Numerous studies emphasize the disruptions of the kidney-brain axis may contribute to the high morbidity of neurological disorders, such as cognitive impairment (CI) in the natural course of chronic kidney disease (CKD). Although the pathophysiology of the kidney-brain axis has not been fully elucidated, epidemiological data indicate that patients at all stages of CKD have a higher risk of developing CI compared with the general population. In contrast to other reviews, we mentioned some commonly used medicines in CKD that may play a pivotal role in the pathogenesis of CI. Revealing the pathophysiology interactions between kidney damage and brain function can reduce the potential risk of future CI. This review will deeply explore the characteristics, indicators, and potential pathophysiological mechanisms of CKD-related CI. It will provide a theoretical basis for identifying CI that progresses during CKD and ultimately prevents and treats CKD-related CI.
PURPOSE: A hair dyeing composition containing green tea catechin and pH adjusting agent is provided to excellent dyeing property and color lasting property. CONSTITUTION: A hair dyeing composition contains a first agent containing 0.01-99.0 weight% of green tea catechin and 0.01-30 weight% of pH adjusting agent and a second agent containing 0.1-10 weight% of mordant. The first agent further contains gallic acid or derivatives thereof. The pH adjusting agent is L-arginine, monoethanol amine, triethanol amine, potassium hydroxide, sodium hydroxide, aminomethyl propanol, phosphoric acid, glycolic acid, citric acid, or acetic acid. The first agent is formulated in powder, liquid, cream, lotion, or gel. The second agent is formulated in liquid, cream, lotion, or gel.
A prosthetic foot (70) incorporates a foot keel (77) and a calf shank (72) connected to the foot keel to form an ankle joint area of the prosthetic foot. The foot keel has forefoot and hindfoot portions and an upwardly arched midfoot portion extending between the forefoot and midfoot portions. The calf shank includes a downward convexly curved lower end  which is adjustably attached at a portion thereof to the foot keel by way of a releasable fastener arrangement. The upper end of the calf shank is movable longitudinally of the foot keel in response to force loading and unloading the calf shank during use of the prosthetic foot. A device (71) connected between the ends of the calf shank limits the extent of the motion of the upper end of the calf shank relative to the lower end and foot keel. The upper end of the calf shank can include an alignment coupler device (92) thereon having adjustable slide mechanisms to adjust the media/lateral and anterior/posterior position of the calf shank relative to a supporting structure on the leg of the person using the prosthetic foot.